A detailed history of M&T Bank Corp transactions in Argenx Se stock. As of the latest transaction made, M&T Bank Corp holds 4,307 shares of ARGX stock, worth $2.71 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,307
Previous 4,307 -0.0%
Holding current value
$2.71 Million
Previous $2.34 Million -0.0%
% of portfolio
0.01%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$434.22 - $551.9 $125,489 - $159,499
289 Added 7.19%
4,307 $2.34 Million
Q2 2024

Jul 31, 2024

BUY
$356.01 - $451.55 $359,926 - $456,517
1,011 Added 33.62%
4,018 $1.73 Million
Q1 2024

May 07, 2024

BUY
$356.95 - $413.29 $36,051 - $41,742
101 Added 3.48%
3,007 $1.18 Million
Q4 2023

Feb 06, 2024

SELL
$338.91 - $506.01 $53,547 - $79,949
-158 Reduced 5.16%
2,906 $1.11 Million
Q3 2023

Nov 02, 2023

SELL
$369.35 - $548.43 $31,764 - $47,164
-86 Reduced 2.73%
3,064 $1.51 Million
Q2 2023

Aug 09, 2023

BUY
$360.14 - $422.58 $6,842 - $8,029
19 Added 0.61%
3,150 $1.23 Million
Q1 2023

May 11, 2023

BUY
$334.23 - $403.65 $1.05 Million - $1.26 Million
3,131 New
3,131 $1.17 Million
Q3 2021

Oct 28, 2021

SELL
$295.0 - $350.58 $209,745 - $249,262
-711 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$257.11 - $319.92 $90,245 - $112,291
-351 Reduced 33.05%
711 $214,000
Q1 2021

May 06, 2021

SELL
$268.3 - $380.31 $12,878 - $18,254
-48 Reduced 4.32%
1,062 $293,000
Q4 2020

Feb 12, 2021

BUY
$248.13 - $308.36 $21,091 - $26,210
85 Added 8.29%
1,110 $327,000
Q3 2020

Nov 06, 2020

SELL
$215.51 - $272.51 $94,177 - $119,086
-437 Reduced 29.89%
1,025 $269,000
Q2 2020

Jul 29, 2020

BUY
$127.44 - $232.72 $186,317 - $340,236
1,462 New
1,462 $330,000
Q1 2020

May 14, 2020

SELL
$108.83 - $165.23 $150,511 - $228,513
-1,383 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$106.59 - $164.21 $147,413 - $227,102
1,383 New
1,383 $222,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.